11/6/2025 9:36:23 PM Comparative Efficacy Studies No Longer a Default for Biosimilars | Alston & Bird By Cathy Burgess Benjamin Wolf Yifan Wang Our FDA: Drug & Device Team examines the FDA’s new draft guidance that allows biosimilar developers to rely more on analytical and...
/Passle/684ab3969b37aca8151f950e/SearchServiceImages/2025-11-06-21-36-12-283-690d14cc343418341b081054.jpg)